Since the Federal Drug Administration approved a new neuroendocrine tumor therapy drug in January, the first patient in Wisconsin recently received the treatment at the University of Wisconsin Carbone Cancer Center. Lutetium Lu 177 dotatate — known as Lutathera — is the first radioactive drug that has been approved to treat advanced NETs affecting the … Continue reading UW cancer facility first in Wisconsin to implement newly approved radioactive drug treatment